Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections

Authors

Claudia Crimi^{1*}, Alberto Noto^{2,3}, Andrea Cortegiani⁴, Pietro Impellizzeri⁵, Mark Elliott⁶, Nicolino Ambrosino⁷, Cesare Gregoretti⁴

Affiliations

¹ Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Department of Clinical and Experimental Medicine, University of Catania, Italy

² Department of Anesthesia and Intensive Care, AOU "Policlinico G. Martino", University of Messina, Italy

³ National Research Council (CNR), Institute for Chemical and Physical Processes (IPCF), Messina, Italy

⁴ Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy

⁵ Department of Clinical and Experimental Medicine, Section of Respiratory Medicine, A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Italy

⁶ Department of Respiratory Medicine, St James's University Hospital, Leeds, UK

⁷ Istituti Clinici Scientifici Maugeri, IRCCS. Istituto di Montescano, Italy

*Corresponding author:

Claudia Crimi

Respiratory Medicine Unit

Department of Clinical and Experimental Medicine, University of Catania

A.O.U. "Policlinico-Vittorio Emanuele",

Via Santa Sofia, 78

Catania, 95123, Italy

E-mail:dott.claudiacrimi@gmail.com

ABSTRACT

Introduction: Noninvasive respiratory support (NRS) such as noninvasive ventilation (NIV) and high flow nasal therapy (HFNT) have been used in the treatment of acute hypoxemic respiratory failure (AHRF) related to the coronavirus disease (COVID-19) and other viral infections. However, there is a lack of consensus in favor of or against NRS use due to the risks of worsening hypoxemia, intubation delay, and aerosols environmental contamination associated with the use of these tools. We aimed to summarize the evidence on the use of NRS in adult patients with COVID-19 and other viral pneumonia (i.e. H1N1, SARS, MERS) and AHRF. We also searched for studies evaluating the risk of aerosolization/contamination with these tools.

Evidence Acquisition: We searched MEDLINE, PubMed EMBASE and two major preprint servers (biorXiv and medRxiv) from inception to April 14, 2020, for studies on the use of respiratory support in AHRF and viral pneumonia.

Evidence Synthesis: The search identified 4086 records and we found only one randomized controlled trial out of 58 studies included, with great variabilities in support utilization and failure rates. Fifteen studies explored the issue of aerosolization/contamination showing a high risk of airborne transmission via droplets generation during the use of these modalities

Conclusions: Use of NRS and treatment failure in the context of COVID-19 and viral infection associated-AHRF, varied widely. Dispersion of exhaled air is different depending on the type of respiratory therapies and interfaces. Data from randomized controlled trials are lacking.

Keywords: noninvasive respiratory support, acute hypoxemic respiratory failure, high flow nasal cannula, noninvasive ventilation, viral pneumonia, COVID-19, H1N1, MERS, influenza.

INTRODUCTION

Viruses are the most common causes of respiratory infections and are responsible for pneumonia in over 20% of cases ¹. Lately, new viruses associated with recent outbreaks have been discovered, such as a new strain of coronavirus, SARS-CoV-2 ².

In the early months of 2020, coronavirus disease 2019 (COVID-19) rapidly became a public health emergency requiring hospitalization in approximately 14% of infected patients ², and it is associated with severe acute hypoxemic respiratory failure (AHRF) in nearly 30% of hospitalized patients requiring oxygen and noninvasive respiratory support (NRS) and intensive care unit (ICU) admission in approximately 5% of cases ²⁻⁴.

COVID-19 has spread rapidly, overwhelming hospitals and facing the challenging situation that the demand for ICU beds outstrip capacity worldwide. Therefore, NRS such as noninvasive ventilation (NIV), continuous positive airway pressure (CPAP) and high flow nasal therapy (HFNT) represent an essential component of the global response to this emerging infection since it may be performed outside the ICU ⁵, limiting the need for critical care resources and invasive ventilation (IMV). Wang and coworkers ⁴ showed that over 50% of patients with AHRF due to SARS-CoV-2 infection received NRS in China. Yet, the Food and Drug Administration has recently provided guidance that allows hospitals to modify home respiratory devices, to ensure the availability of the greatest possible number of systems for delivering NRS to the highest number of patients during the public health emergency ⁶.

Nevertheless, the beneficial effects of applying NRS in patients with viral pneumonia associated-AHRF remain controversial ^{7,8}, due to the possible rapid deterioration of hypoxemia and the higher rate of endotracheal intubation (ETI) ⁹; furthermore, its safety in diseases transmittable via respiratory route is unclear.

We conducted a review to summarize the clinical evidence on the use of NRS in viral pneumonia and to explore the risk of environmental contamination in healthcare settings.

METHODS

Literature search

We conducted searches in Medline, PubMed, and EMBASE for published randomized control trials (RCTs) and observational studies (both prospective and retrospective) in adult patients from inception to April 14, 2020, in English only.

Searches were performed using a combination of the following terms: *COVID-19*, *virus infections*, *noninvasive respiratory support*, *NIV*, *BiPAP*, *CPAP*, *HFNT*, and *pneumonia*. We also considered articles evaluating aerosolization into the environment during respiratory therapies.

To increase the sensitivity, we searched in preprint servers (biorXiv and medRxiv) for COVID-19 and SARS-Cov-2 articles¹⁰⁻¹³. Additional relevant articles were identified through bibliography of the retrieved papers (“snowballing method”). Detailed search strategy was reported in the **Supplementary material 1**.

Two investigators (CC, AN) independently screened the titles and the abstracts retrieved, and selected full-text of relevant articles, (**Supplementary material 2**). Disagreements between reviewers were discussed and a third author (AC) was consulted if agreement could not be reached.

RESULTS

The literature search identified 3089 records and 997 articles from preprint servers (780 medRxiv, 217 bioRxiv). Review of titles and abstracts retrieved 404 potentially relevant full-texts with 4 from the preprint server. After full-text analysis 8 articles were added from snowballing and 354 articles were excluded for the following reasons: 191 focused on pediatric populations, 22 focused on pneumonia in immunocompromized patients, 49 were case reports, 40 were abstract/conference papers, 14 editorial/letter, 13 reviews, 10 not available, 15 not relevant. A total of 58 articles were reviewed, (**Supplementary material 2**). The review was conducted in accordance to PRISMA statement..

COVID-19

COVID-19 is a recent and still ongoing pandemic that has spread quickly, overwhelming hospitals, increasing the demand for critical care services with a mortality rate in patients requiring advanced respiratory support ranging from 62 to 97%¹⁴⁻¹⁶, with nearly 25% of patients remaining critically ill¹⁷. In this context, an increasing number of publications are becoming available on the use of NRS^{3, 4, 10-13, 16-21}, mostly from China^{3, 4, 10-13, 16, 18, 20, 21}, but also from Italy¹⁹ and USA¹⁷.

The percentage of patients requiring NRS varied greatly among the studies, ranging from 11% to 96%, (Figure 1), with higher usage rate in China (62% on average), and lower rate in North America (20%)¹⁷ and Italy (11%)¹⁹, with Italian authors reporting a higher need for IMV in their critically ill population compared with other studies^{20, 21}.

Noninvasive support was mainly delivered in ICU, apart from two studies that described its use outside the ICU settings in 20%³ and 50% of their population²⁰, respectively. The overall mean utilization rate among studies was 31% for HFNT^{4, 10, 12, 13, 17, 18, 20} and 30% for NIV^{4, 10-13, 17-21}, with Wang et al.¹⁸ reporting a prevalent use of HFNT (63%) as initial respiratory support since that, because of the emergency, the clinical staff involved in patients’ management had a heterogeneous background and little or no experience with NIV.

Failure rate was mainly explored in Chinese studies and varies widely as shown in the **Supplementary material S3**, ranging from 52%²¹ to 92%²⁰; however, data are not uniform since sometimes NIV was used as a rescue therapy after HFNT failure¹⁸.

Mortality rate was rarely reported in the studies included. Yang et al.¹⁶ in their cohort of 52 critically ill patients showed a 48% mortality rate (16/33) for patients receiving HFNT and 72% (23/26) for patients treated with NIV as the first-line treatment or as an escalation of care.

Influenza A-H1N1

Influenza A (H1N1), also called swine flu, spread globally at the beginning of 2009, starting from Mexico and causing a febrile respiratory infection, reporting mortality of more than 50% in mechanically ventilated patients²².

As shown in Figure 2, a high variability (from 13 to 80%) in NRS utilization rate was found among patients requiring ventilatory assistance, with wide variations in success rate reported within similar geographical areas²³⁻²⁷.

Failure rate was very heterogeneous among the studies as shown in Table 1 and **Supplementary material S4**. This wide variability is caused by the different analytical methods used in each study: type of enrolled patient populations, sample size and criteria for ETI.

Few studies^{25, 28-30} reported the specific criteria before NRS initiation. Almost all the studies were conducted in ICU settings^{23-27, 30-42} except two that were performed in both ICUs and High Dependency Units (HDUs)^{28, 29}.

Particularly, modes and settings of NRS delivery were rarely described^{23, 27-30, 35, 39, 43}. Interfaces used were specified in only 6 out of 21 studies (28%)^{27-30, 35, 39}. Oro-nasal and total face masks^{28, 29, 35, 39} were the most widely used interfaces for NIV/CPAP, with the use of the helmet reported only in the Spanish experience²⁷, as shown in Table 1.

Three studies highlighted predictors of success^{25, 29, 37}. Factors associated with a positive response to NIV treatment were explored by Masclans et al.²⁵ [less radiological involvement, hemodynamic stability and a sequential organ failure assessment (SOFA) score < 7]; similar results [fewer pulmonary lobes involved, lower Simplified Acute Physiology Score (SAPS II) and SOFA score, higher arterial oxygen tension to inspiratory oxygen fraction (P/F)] were showed by Vivarelli et al.²⁹ and by Linko et al.³⁷.

Predictors of failure were highlighted in three studies^{26, 28, 41}. Rello and coworkers³⁰ showed that HFNT failure was associated with a SOFA score value of 4 or more, Acute Physiology And Chronic Health Evaluation II score (APACHE II) of 12 or more and shock; Bai et al.⁴¹ identified a higher APACHE II scores on presentation as associated with unfavorable NIV outcome,

while Nicolini and coworkers²⁸ found that high SAPS II score, P/F ratio <127 and the new infectious complications related to the ICU stay were determinants for NIV failure.

Data on mortality are very heterogeneous among the studies and only six authors described a specific NIV failure/success-related mortality^{25, 28, 36, 39, 40, 42} with no changes in terms of mortality compared to patients who were directly intubated in two studies^{36, 40}.

Severe Acute Respiratory Syndrome (SARS)

SARS-CoV was identified in 2003 in Hong Kong and caused AHRF in nearly 25% of affected patients⁴⁴.

In a retrospective analysis⁴⁵, NIV was effective in preventing ETI in 70% of patients (14/20) with a low APACHE score. In a study⁴⁶ with a random assignment to 4 treatments, the best response (no deaths) was seen in the group of 60 patients receiving early high-dose steroids and nasal CPAP. Failure rates are shown in **Supplementary material 5**.

Influenza

Seasonal influenza epidemics may be associated with high morbidity and mortality, especially in older patients, since symptoms may progress quickly to respiratory distress and extensive pulmonary involvement⁴⁷.

In an analysis of 22 patients admitted to ICU for influenza-related AHRF in Turkey, all patients were treated with NIV with a full face mask as a first-line intervention⁴⁸ with a survival rate of 78% in patients where NIV was successful.

In a report⁴⁹ of 651 patients with influenza and respiratory syncytial virus, 32% (61/191) developed pneumonia and 33% of them required ventilatory support, predominantly noninvasive (70%). A secondary analysis from a large prospective observational multi-center study⁵⁰ of 1898 critically ill subjects admitted to the ICU comparing patients who received NIV or IMV immediately after ICU admission showed that NIV was the treatment of choice in 42.4% of them, with 56.8% treatment failure rate in more severe patients with higher APACHE II and SOFA scores and more pronounced radiological infiltrates, and higher mortality (38%). Patients with a SOFA score ≥ 5 had a 3-fold risk of NIV failure; moreover, a higher NIV success rate was reported in patients with chronic obstructive pulmonary disease (COPD), (73.7%).

A retrospective Spanish study⁵¹ of 219 hospitalized patients with AHRF showed that patients older than 80 years old were more likely to receive NIV treatment as compared to younger patients (22% vs 9.3%).

A recent observational study by Ding et al.⁵² on patients with moderate-to-severe ARDS (SpO₂>95%) showed the possibility of successfully managing patients with early HFNT combined with prone positioning or NIV alone, improving oxygenation and avoiding intubation in nearly 55% of the patients (11/20).

Finally, analyzing viral-related COPD exacerbation, a study⁵³ of 76 patients with acute exacerbations of COPD showed that NIV was successfully used in nearly 23 episodes (8.8%). In another study on 105 COPD patients with viral exacerbation, 61 patients (57%) received NIV alone, with 17 (16%) receiving both NIV and ETI and only 29 (27%) being intubated without NIV⁵⁴.

Middle East respiratory syndrome (MERS)

The use of NIV has also been studied in 302 critically ill patients with MERS⁵⁵ where NIV was provided in 105 (35%) patients, presenting with a lower baseline SOFA score and less extensive infiltrates on chest radiograph compared with patients managed with IMV with similar ICU and hospital length of stay. The intubation rate in the NIV group was 92.4%, with a 90-day mortality of 65.7% vs. 76.1% of the IMV group; the use of NIV was not independently associated with mortality. Failure rates are shown in **Supplementary material 5**.

Viral aerosol droplet generation

Biohazardous aerosols are routinely generated in hospitals by processes such as breathing, coughing, sneezing, ETI, NIV, delivery of medication by nebulization. Aerosol generating procedures may expose health care workers to bacterial/viral pathogens causing acute respiratory infections. Some procedures (ETI, NIV, tracheotomy, and bag ventilation) are believed to spread more aerosols and droplets⁵⁶.

Currently, droplets are defined as being >5 µm in diameter that fall rapidly to the ground under gravity and therefore are transmitted only over a limited distance (e.g. ≤1 m). Airborne transmission is different from droplet transmission as it refers to the presence of microbes within droplet nuclei, which are generally considered as being particles <5µm in diameter that can remain in the air for long periods and be transmitted to others over distances greater than 1 m⁵⁷.

Noninvasive ventilation is a large (10 µm) droplet (not aerosol)-generating procedure⁵⁸. Due to their large mass, most fall out on to local surfaces within 1 m. Droplets' productions during NIV are greatly reduced with the use of non-vented full-face masks connected with a viral/bacterial filter⁵⁸, Figure 4. We identified 15 studies evaluating aerosolization during NRS.

Hui et al.⁵⁹ measured airflow using a smoke-marker and confirmed the difference between vented and non-vented masks, measuring the maximum exhaled air distances with different oxygen

therapy devices: nasal cannula, Venturi mask, and a non-rebreathing mask, Figure 4. Authors also recommended that a Whisper swivel valve would not be advisable in managing patients with febrile respiratory illness of unknown etiology⁶⁰, especially in the setting of an influenza pandemic, even if the addition of a viral filter before the expiratory port can reduce aerosol emission. It is also important to avoid the use of higher inspiratory positive airway pressures, which could lead to a wider distribution of exhaled air and possible room contamination^{60, 61}. It has been demonstrated that the helmet is the preferred NIV interface to reduce leakage and droplet contamination (NIV configuration with double limb circuit) especially the model provided with a neck seal. A helmet without a good seal at the neck can produce a radial leakage of 270mm⁶².

The leakage produced during procedures and ventilation strategy led to different room contamination accordingly to the room dimensions (i.e. more contamination in smaller rooms)⁶³.

The clinical usefulness of NRS in AHRF is still debated, but moreover, in the context of viral pneumonia, it is important to understand how a flow up to 60 l/m impact on the spread of droplets. Recent data shows that HFNT did not increase the spread of exhaled air despite operating at higher flow rates, possibly because of the very low positive end-expiratory pressure (PEEP) generated⁶⁴. Another study, not based on simulation, has shown that HFNT did not increase bacterial contamination (airborne and surface) compared to an oxygen mask⁶⁵.

Most researches were based on the smoke visualization of the exhaled air and not on the direct measurements of the viral droplets, with the exceptions of only two studies^{58, 65}. Therefore, we can consider it as the maximum boundaries and trajectory of the droplets dispersion. Further studies with direct measurements of pathogen agents are required to plan healthcare protection during viral infection.

DISCUSSION

To the best of our knowledge, this is the most up to date systematic review evaluating the use of NRS in the treatment of AHRF related to viral infections. We identified a large body of literature that describes current clinical practices and challenges of noninvasively treating those patients. However, most of the studies had a non-randomized design, so uncertainty remains on the safety and effectiveness of NRS use in this setting. Our results should encourage the scientific community to promote future research in this area to fill the knowledge gap, especially in the current context of the COVID-19 pandemic.

There is a theoretical strong rationale for the use of NRS as compare to standard oxygen in patients with pulmonary infiltrates. The application of PEEP through NIV/CPAP can effectively increase functional residual capacity and re-inflate collapsed alveoli, improving

ventilation/perfusion matching⁶⁶. High-flow nasal cannula generates a small PEEP effect, improving oxygenation, respiratory mechanics and end-expiratory lung volume, reducing the work of breathing and offering good comfort to the patient^{8, 67}.

Furthermore, physicians are likely to use both techniques in clinical practice. In a recent survey of 235 ICU physicians in France⁶⁸, HFNT and NIV use was perceived as relevant in managing AHRF by all the participants and in a previous European survey on NIV practices⁶⁹ physicians reported the use of NIV for *de novo* ARF in about 15-20% of patients, with intensivists more likely to use it than pulmonologists.

Nevertheless, clinical benefits are less clear and guidelines⁷ did not provide any recommendation in favor or against NIV use in both *de novo* and viral pandemic AHRF because the published literature so far did not identify a clear advantage in terms of outcomes⁷⁰; similar conflicting evidence exists on the use of HFNT as well^{8, 71}. However, during the H1N1 pandemic in 2009, a statement of international societies⁷² suggested that NIV should not be used routinely as an alternative to IMV but it might be applied in highly selected cases to prevent progression of AHRF and need for ETI or as “ceiling” treatment during pandemics.

In the examined studies we found wide variability in terms of utilization rate, timing of initiation, operational mode and settings, types of interface, where to perform it and, cut-off parameters for withdrawal. The results of this review provide an outline of common themes for future research and judicious reflections: what might be the role of NRS in viral pneumonia AHRF? We believe that the following should be considered.

First, the utilization rate in viral pneumonia-associated AHRF is not uniform among the evaluated studies, ranging from 11% to 96% during the COVID-19 pandemic. Among noninvasive devices, HFNT seems more used than NIV^{10, 12, 13, 18, 20} in the COVID-19 scenario except in 2 studies^{4, 17}, probably because it requires less expertise¹⁸ and it can be easily used also outside the ICU settings⁵. Little information on success or failure rate is available^{18, 21} with a reported overall mortality of patients requiring advanced respiratory support of about 63%¹⁴ or higher¹⁶. Similar fluctuating usage rates were reported during H1N1 and MERS/SARS outbreaks ranging from 13% to 80% and from 35 to 100%, respectively, with NIV predominantly used since HFNT was released in 2009. Moreover, we found striking differences in the reported success rate, going from encouraging^{24, 28, 45} to concerning^{36, 38, 55}, highlighting the need for performing NRS only in highly expert centers²⁸ and with well-defined patient selection and ETI criteria.

Second, timing and patient selection should be clearly defined. Most of the examined studies showing benefits of NIV suggested the early enrollment (P/F<300)²⁸, or to start in subjects with

less severe disease^{25, 29, 30, 55}, even if these patients might have got better anyway. Few studies described criteria of initiation of NRS^{29, 48, 50}; most of the trials are retrospective and sometimes the decision to start was made by the physician on duty on clinical rounds. Based on these findings, the interval between the onset of AHRF and the initiation of a gentle NRS trial is crucial to “buy time” for medical therapy to take effect and possibly reverse the underlying cause of respiratory failure. Likewise, a rapid and wise assessment of slight variations in gas exchange and patient status has to be made during trials to avoid the risk of intubation delay. This is extremely important since if NIV is successful, patients’ mortality is negligible, but if NIV fails, mortality is higher as compared to patients receiving ETI as first-line treatment⁷³. Similarly, patients intubated after HFNT showed greater mortality if experience late failure (>48h, 66% vs. <48h, 39%)⁸.

Third, modes and settings are heterogeneous and not specified. Almost all the examined studied reported usage but do not describe in-depth modes (i.e. BiLevel vs. CPAP)³, settings^{23, 27-30, 35, 39, 43} (i.e. levels of PEEP or pressure support). This is an important aspect to consider since CPAP may be useful in reversing atelectasis but the inadequate pressure support in patients with high respiratory drive may generate patient self-induced lung injury (P-SILI)⁷⁴. Furthermore, NIV cannot control tidal volumes and it cannot guarantee lung-protective ventilation in nearly 75% of patients, which might worsen ventilator-induced lung injury⁷⁵. Very few studies specify the type of interface used^{27-30, 35, 39, 52}. The selection of non-vented interfaces or helmet for delivering NIV/CPAP and the application of a surgical mask when using HFNT is crucial to reduce the risk of viral droplets dispersion with the risk of transmitting the infection to healthcare workers⁶⁵ that should always use personal protective equipment to protect themselves⁷⁶. In particular, helmet may confer advantages over the face mask: it can minimize virus spread within treatment facility⁶², and it can be used without a ventilator connected to fresh gas flow⁷⁷, even if it has to be considered that some hospitals may have difficulties in coping with the high oxygen flow demand.

Fourth, hospital settings are heterogeneous. Only in two studies, NRS has been performed also in non-ICU settings^{3, 20}. Where NRS is performed in each hospital around the world is not uniform and might depend upon hospitals’ internal organization and total numbers of ICU beds available. An underestimation of the progression and severity of *de novo* AHRF in patients hospitalized in general wards has been shown by Quentin et al.⁷⁸ who reported that nearly 10% of patients already met the criteria for ARDS but were likely to be transferred to an ICU with a median of 6 days after admission. On the other hand, the ICU might expose the patient to additional risks such as infections that might contribute to unfavorable outcomes²⁸ and it can be excessively costly for patients with mild ARDS, especially during pandemics, where ICU resources should be limited

to the sicker patients . Moreover, NIV delivery is an added challenge for the clinician: it is highly time-consuming and needs specific skills to be performed. Probably, to get the most from this noninvasive strategies, specialized care provided by a respiratory and highly expert critical care team²⁸ and an appropriate location such as High Dependency Units (HDUs)^{28, 29} might be the best compromise to accommodate the major number of patients, deliver cost-effective NRS trials and relieve the burden of ICU beds availability, as it has been described in Italy during the COVID outbreak¹⁹.

Finally, predictors of failure or success are lacking. Tools and scores to predict HFNT and NIV failure have been developed. A Rox index⁷⁹ (SpO₂/FiO₂)/respiratory rate < 3.85 at 12 hours identified patients at high risk of failure for HFNT trial as well as the HACOR (heart rate, acidosis, consciousness, oxygenation, and respiratory rate) scale > 5 at 1 h for NIV⁸⁰. However, these tools were not used in the examined studies. Few studies^{25, 26, 28, 35} identified predictors of failure. None of the studies describe what could be considered an acceptable clinical response or a good time-frame for withdrawal or which is the best strategy to wean the patient (a stepwise reduction of the amount or of the time of support).

We should recognize that most of the NRS studies were inadequately designed to evaluate its role in viral pneumonia. Nevertheless, although RCTs remain the most robust method to study the effects of a medical tool, in specific situations such as pandemics, it might be almost impossible for clinicians to spend efforts in performing properly designed clinical trials since they should focus all available resources on saving lives. Therefore, the studies carried out in real-life especially in this contingency are crucial to confirm the effectiveness of previously studied medical devices.

Probably in the catastrophic scenario of a pandemic, it might appear reasonable to try an early NRS to potentially prevent the progression of AHRF severity and this is likely the reason why in the COVID-19 era, any type of NRS⁸¹, even repurposed techniques⁶ are used to accommodate the major number of patients possibly limiting ICU resources.

CONCLUSIONS

Despite the lack of robust scientific evidence, NRS is widely used in the treatment of viral pneumonia-related AHRF, with the advantage of reducing the burden of critical care resources utilization but with the risk of delaying but not avoiding intubation.

We found great variability in NRS utilization and treatment failure among different geographic areas and sometimes within the same country. Nevertheless, the published data provided very limited and unclear information about modes, settings, interfaces, locations, timing of initiation, or withdrawal of NRS.

Further high-quality studies are needed in these settings, to explore the efficacy of a system with potential viral droplet spread and possible contamination of health-care workers.

KEY MESSAGES

- Noninvasive respiratory support is widely used in the treatment of viral pneumonia-related acute hypoxemic respiratory failure, despite the lack of solid scientific evidence.
- There is a great variability in noninvasive respiratory support utilization and failure rate and unclear information about modes, settings, interfaces, locations, timing of initiation, or withdrawal.
- There is a lack of randomized control trial that needed to be performed to explore the efficacy of a potential viral droplet generation system such as noninvasive respiratory support in the context of viral infections.

References

1. Shorr AF, Fisher K, Micek ST, Kollef MH. The burden of viruses in pneumonia associated with acute respiratory failure: an underappreciated issue. *Chest*. 2018;154:84-90.
2. Dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University. 2020 [citedDate Cited]; Available from:<https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
5. Cabrini L, Landoni G, Oriani A, Plumari VP, Nobile L, Greco M, et al. Noninvasive ventilation and survival in acute care settings: a comprehensive systematic review and metaanalysis of randomized controlled trials. *Crit Care Med*. 2015;43:880-8.
6. FDA US. Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. 2020 [citedDate Cited]; Available from:<https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19>.
7. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017;50.
8. Helviz Y, Einav S. A Systematic Review of the High-flow Nasal Cannula for Adult Patients. *Crit Care*. 2018;22:71.
9. Namendys-Silva SA, Hernandez-Garay M, Rivero-Sigarroa E. Non-invasive ventilation for critically ill patients with pandemic H1N1 2009 influenza A virus infection. *Crit Care*. 2010;14:407.
10. Xu Y, Xu Z, Liu X, Cai L, Zheng H, Huang Y, et al. Clinical findings in critically ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study. *medRxiv* 2020030320030668;. 2020.
11. Xu Y, Li Y, Zeng Q, Lu Z, Li Y, Wu W, et al. Clinical Characteristics of SARS-CoV-2 Pneumonia Compared to Controls in Chinese Han Population. *medRxiv* 2020030820031658;. 2020.
12. Zheng Y. SL, Xu M., Pan J., Zhang Y., Fang X., Fang Q., H. C. Clinical characteristics of 34 COVID-19 patients admitted to ICU in Hangzhou, China. *medRxiv* 2020041220062604;. 2020.
13. Liao XC, H. Wang, B. Jin, X. Li. Z. Zhang, Z. Li, W. Tang, J. Wang, J. Shi, R. Zhen, X. Wang, M. Lei, X. Gong, Y. Lv, S. Jia, C. Chen, L. Shang, J. Yang, M. Wei, H. Zhang, Y. Yang, X. Shen, H. Xiao, X. Yang, J. Lui, C. Wu, Q. Wang, W. Yang, J. Yin, W. Xie, X. Tian, Y. Liu, H. Shuai, B., Zhang WS, X. Kang, Y. Critical Care for Severe COVID-19: A Population-based Study from a Province with Low Case-fatality Rate in China. *medRxiv* 2020032220041277;. 2020.
14. icnarc. [citedDate Cited]; Available from:<https://www.icnarc.org/About/Latest-News/2020/04/04/Report-On-2249-Patients-Critically-Ill-With-Covid-19>.
15. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet*. 2020;395:1014-5.
16. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020.
17. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA*. 2020.

18. Wang K ZW, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. 2020.
19. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020.
20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054-62.
21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
22. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. *N Engl J Med*. 2009;361:680-9.
23. Rios FG, Estenssoro E, Villarejo F, Valentini R, Aguilar L, Pezzola D, et al. Lung function and organ dysfunctions in 178 patients requiring mechanical ventilation during the 2009 influenza A (H1N1) pandemic. *Crit Care*. 2011;15:R201.
24. Estenssoro E, Rios FG, Apezteguia C, Reina R, Neira J, Ceraso DH, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. *Am J Respir Crit Care Med*. 2010;182:41-8.
25. Masclans JR, Perez M, Almirall J, Lorente L, Marques A, Socias L, et al. Early non-invasive ventilation treatment for severe influenza pneumonia. *Clin Microbiol Infect*. 2013;19:249-56.
26. Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. *Crit Care*. 2009;13:R148.
27. Belenguer-Muncharaz A, Reig-Valero R, Altaba-Tena S, Casero-Roig P, Ferrandiz-Selles A. [Noninvasive mechanical ventilation in severe pneumonia due to H1N1 virus]. *Med Intensiva*. 2011;35:470-7.
28. Nicolini A, Tonveronachi E, Navalesi P, Antonelli M, Valentini I, Melotti RM, et al. Effectiveness and predictors of success of noninvasive ventilation during H1N1 pandemics: a multicenter study. *Minerva Anestesiol*. 2012;78:1333-40.
29. Vivarelli M PA, Gatto P, Truglio PA, Santo M, Ferraioli G, Nicolini A. Management of severe respiratory failure following influenza A H1N1 pneumonia. *Italian Journal of Medicine*. 2013;7:293-9.
30. Rello J, Perez M, Roca O, Poulakou G, Souto J, Laborda C, et al. High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v. *J Crit Care*. 2012;27:434-9.
31. Nin N, Soto L, Hurtado J, Lorente JA, Buroni M, Arancibia F, et al. Clinical characteristics and outcomes of patients with 2009 influenza A(H1N1) virus infection with respiratory failure requiring mechanical ventilation. *J Crit Care*. 2011;26:186-92.
32. Marin-Corral J, Climent C, Munoz R, Samper M, Dot I, Vila C, et al. Patients with influenza A (H1N1)pdm09 admitted to the ICU. Impact of the recommendations of the SEMICYUC. *Med Intensiva*. 2018;42:473-81.
33. Gogia A. KP, Kakar A. Mortality predictors of H1N1 influenza outbreak in 2015–A cross-sectional study. *Current Medicine Research and Practice*. 2017;7:44-6.
34. Zhang PJ, Li XL, Cao B, Yang SG, Liang LR, Gu L, et al. Clinical features and risk factors for severe and critical pregnant women with 2009 pandemic H1N1 influenza infection in China. *BMC Infect Dis*. 2012;12:29.
35. Hernandez Garces H, Navarro Lacalle A, Lizama Lopez L, Zaragoza Crespo R. Risk factors associated to noninvasive ventilation failure in primary influenza A pneumonia in the critical care setting. *Med Intensiva*. 2020.

36. Brink M, Hagberg L, Larsson A, Gedeberg R. Respiratory support during the influenza A (H1N1) pandemic flu in Sweden. *Acta Anaesthesiol Scand*. 2012;56:976-86.
37. Linko R, Pettila V, Ruokonen E, Varpula T, Karlsson S, Tenhunen J, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. *Acta Anaesthesiol Scand*. 2011;55:971-9.
38. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. *JAMA*. 2009;302:1872-9.
39. Timenetsky KT, Aquino SH, Saghabi C, Taniguchi C, Silvia CV, Correa L, et al. High success and low mortality rates with non-invasive ventilation in influenza A H1N1 patients in a tertiary hospital. *BMC Res Notes*. 2011;4:375.
40. Chawla R, Kansal S, Chauhan M, Jain A, Jibhkate BN. Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): Experiences of a tertiary care center. *Indian J Crit Care Med*. 2013;17:275-82.
41. Bai L, Gu L, Cao B, Zhai XL, Lu M, Lu Y, et al. Clinical features of pneumonia caused by 2009 influenza A(H1N1) virus in Beijing, China. *Chest*. 2011;139:1156-64.
42. Koegelenberg CF, Iruen EM, Cooper R, Diacon AH, Taljaard JJ, Mowlana A, et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. *QJM*. 2010;103:319-25.
43. Bitar RA. Population Effects of Influenza A(H1N1) Pandemic among Health Plan Members, San Diego, California, USA, October-December 2009. *Emerg Infect Dis*. 2016;22:255-60.
44. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, et al. Critically ill patients with severe acute respiratory syndrome. *JAMA*. 2003;290:367-73.
45. Cheung TM, Yam LY, So LK, Lau AC, Poon E, Kong BM, et al. Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. *Chest*. 2004;126:845-50.
46. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol*. 2003;52:715-20.
47. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA*. 2003;289:179-86.
48. Ediboglu O, Ataman S, Kirakli C. Characteristics of influenza pneumonia patients admitted to the ICU due to hypoxemic respiratory failure. *Tuberk Toraks*. 2018;66:52-6.
49. Topoulos S, Giesa C, Gattermann S, Fussen R, Lemmen S, Ewig S. Analysis of acute respiratory infections due to influenza virus A, B and RSV during an influenza epidemic 2018. *Infection*. 2019;47:425-33.
50. Rodriguez A, Ferri C, Martin-Loeches I, Diaz E, Masclans JR, Gordo F, et al. Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection. *Respir Care*. 2017;62:1307-15.
51. Ramos JM, Garcia-Navarro MM, Gonzalez de la Aleja MP, Sanchez-Martinez R, Gimeno-Gascon A, Reus S, et al. Seasonal influenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, clinical presentation and prognostic factors. *Rev Esp Quimioter*. 2016;29:296-301.
52. Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. *Crit Care*. 2020;24:28.
53. Ko FW, Ip M, Chan PK, Chan MC, To KW, Ng SS, et al. Viral etiology of acute exacerbations of COPD in Hong Kong. *Chest*. 2007;132:900-8.
54. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. *Intensive Care Med*. 2006;32:1022-9.

55. Alraddadi BM, Qushmaq I, Al-Hameed FM, Mandourah Y, Almekhlafi GA, Jose J, et al. Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. *Influenza Other Respir Viruses*. 2019;13:382-90.
56. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS One*. 2012;7:e35797.
57. Stetzenbach LD, Buttner MP, Cruz P. Detection and enumeration of airborne biocontaminants. *Curr Opin Biotechnol*. 2004;15:170-4.
58. Simonds AK, Hanak A, Chatwin M, Morrell M, Hall A, Parker KH, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. *Health Technol Assess*. 2010;14:131-72.
59. Hui DS, Chan MT, Chow B. Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. *Hong Kong Med J*. 2014;20 Suppl 4:9-13.
60. Hui DS, Chow BK, Ng SS, Chu LCY, Hall SD, Gin T, et al. Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. *Chest*. 2009;136:998-1005.
61. Hui DS, Hall SD, Chan MT, Chow BK, Tsou JY, Joynt GM, et al. Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. *Chest*. 2006;130:730-40.
62. Hui DS, Chow BK, Lo T, Ng SS, Ko FW, Gin T, et al. Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. *Chest*. 2015;147:1336-43.
63. Hui DS, Chow BK, Chu L, Ng SS, Lai ST, Gin T, et al. Exhaled air dispersion and removal is influenced by isolation room size and ventilation settings during oxygen delivery via nasal cannula. *Respirology*. 2011;16:1005-13.
64. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. *Eur Respir J*. 2019;53.
65. Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. *J Hosp Infect*. 2019;101:84-7.
66. L'Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. *Am J Respir Crit Care Med*. 2005;172:1112-8.
67. Cortegiani A, Crimi C, Noto A, Helviz Y, Giarratano A, Gregoretti C, et al. Effect of high-flow nasal therapy on dyspnea, comfort, and respiratory rate. *Crit Care*. 2019;23:201.
68. Besnier E, Hobeika S, S NS, Lambiotte F, Du Cheyron D, Sauneuf B, et al. High-flow nasal cannula therapy: clinical practice in intensive care units. *Ann Intensive Care*. 2019;9:98.
69. Crimi C, Noto A, Princi P, Esquinas A, Nava S. A European survey of noninvasive ventilation practices. *Eur Respir J*. 2010;36:362-9.
70. Cortegiani A, Madotto F, Gregoretti C, Bellani G, Laffey JG, Pham T, et al. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. *Crit Care*. 2018;22:157.
71. Cortegiani A, Crimi C, Sanfilippo F, Noto A, Di Falco D, Grasselli G, et al. High flow nasal therapy in immunocompromised patients with acute respiratory failure: A systematic review and meta-analysis. *J Crit Care*. 2019;50:250-6.
72. Conti G, Larrsson A, Nava S, Navalesi P. On the role of non-invasive ventilation (NIV) to treat patients during the H1N1 influenza pandemic. *ERS and ESICM guideline Nov 2009*. 2009.
73. Demoule A, Girou E, Richard JC, Taille S, Brochard L. Increased use of noninvasive ventilation in French intensive care units. *Intensive Care Med*. 2006;32:1747-55.

74. Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. *Am J Respir Crit Care Med*. 2017;195:438-42.
75. Carteaux G, Millan-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. *Crit Care Med*. 2016;44:282-90.
76. Ippolito M, Vitale F, Accurso G, Iozzo P, Gregoretti C, Giarratano A, et al. Medical masks and Respirators for the Protection of Healthcare Workers from SARS-CoV-2 and other viruses. *Pulmonology*. 2020.
77. Esquinas Rodriguez AM, Papadakos PJ, Carron M, Cosentini R, Chiumello D. Clinical review: Helmet and non-invasive mechanical ventilation in critically ill patients. *Crit Care*. 2013;17:223.
78. Quartin AA, Campos MA, Maldonado DA, Ashkin D, Cely CM, Schein RMH. Acute lung injury outside of the ICU: incidence in respiratory isolation on a general ward. *Chest*. 2009;135:261-8.
79. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, et al. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. *Am J Respir Crit Care Med*. 2019;199:1368-76.
80. Duan J, Han X, Bai L, Zhou L, Huang S. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. *Intensive Care Med*. 2017;43:192-9.
81. Winck JC, Ambrosino N. COVID-19 pandemic and non invasive respiratory management: Every Goliath needs a David. An evidence based evaluation of problems. *Pulmonology*. 2020.

NOTES

Conflicts of interest. Dr. Crimi, Dr. Noto, Dr. Impellizzeri, Dr. Ambrosino certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. Dr. Elliott reports personal fees from Philips-Respironics, ResMed, Fisher and Paykel, outside the submitted work. Dr. Cortegiani and Dr. Gregoretti declare a patent pending in association with the University of Palermo- Italy (N°102019000020532 - Italian Ministry of Economic Development) related to the content of this manuscript. Dr. Gregoretti received payment by Philips for consultancies in the developing process of the EVO ventilator and reports personal fees for lectures from Philips, Resmed, Air Liquide, and Vivisol outside the submitted work;

Funding. None.

Authors' contributions.— CC, AN, conceived the content, drafted the manuscript, approved the final version to be submitted. AC conceived the content, assisted with the literature search strategy, helped in writing the manuscript, approved the final version to be submitted. PI conceived the content, helped in writing the manuscript, approved the final version to be submitted. NA, ME, CG helped in writing the manuscript and revised it critically for important intellectual content, approved the final version to be submitted.

Acknowledgements. None.

TABLES

Table 1. Characteristics and outcomes of included studies.

	COUNTRY	DESIGN	POPULATION TYPE N	VENTILATORY SUPPORT N (%)	NRS UTILIZATION RATE N (%)	NRS FAILURE RATE N (%)	NRS TYPE
Wang D. ⁴ <i>JAMA 2020</i>	China	Retrospective SC	SARS-CoV2 138	36 (26 %)	HFNT: 4 (11%) NIV: 15 (42%) NRS: 19 (53%)	NA	NIV/ HFNT
Arentz M. ¹⁷ <i>JAMA Netw Open 2020</i>	USA	Retrospective SC	SARS-CoV2 21	20 (95%)	HFNT: 1 (5%) NIV: 4 (20%) NRS: 5 (25%)	NA	NIV/ HFNT
Grasselli G. ¹⁹ <i>JAMA 2020</i>	Italy	Retrospective MC	SARS-CoV2 1591	1287 (99%)*	NIV: 137 (11%)	NA	NIV
Huang C. ³ <i>Lancet 2020</i>	China	Prospective	SARS-CoV2 41	14 (34%)	NRS: 10 (71%)	NA	NIV/ HFNT
Wang K. ¹⁸ <i>Ann Intensive Care 2020</i>	China	Retrospective	SARS-CoV2 318	27 (8%)	HFNT: 17 (63%) NIV: 9 (3%) NRS: 26 (96%)	HFNT: 7 (41%)	NIV/ HFNT
Zhou F. ²⁰ <i>Lancet 2020</i>	China	Retrospective MC	SARS-CoV2 191	99 (52%)	HFNT: 41 (41%) NIV: 26 (26%) NRS: 67 (68%)	NA	NIV/ HFNT
Guan W. ²¹ <i>NEJM 2020</i>	China	Retrospective MC	SARS-CoV2 1099	67 (6.1%)	NIV: 56 (83%)	NIV: 29 (52%)	NIV
Yang X. ¹⁶ <i>Lancet 2020</i>	China	Retrospective SC	SARS-CoV2 52	NA	NA	NA	NIV/ HFNT
Liao X. ¹³ <i>MedRxiv 2020</i>	China	Retrospective MC	SARS-CoV2 81	63 (77%)	HFNT: 31 (49%) NIV: 22 (35%) NRS: 53 (84%)	HFNT: 6 (19%) NIV: 3 (13%)	NIV/ HFNT

Zheng Y. ¹² <i>MedRxiv 2020</i>	China	Retrospective SC	SARS-CoV2 34	34 (100%)	HFNT: 18 (53%) NIV: 1 (3%)	HFNT: 18 (100%) NIV: NA	NIV/ HFNT
Xu Yang ¹¹ <i>MedRxiv 2020</i>	China	Retrospective MC	SARS-CoV2 69	5 (7%)	NIV: 3 (60%)	NA	NIV
Xu Yonghao ¹⁰ <i>MedRxiv 2020</i>	China	Retrospective MC	SARS-CoV2 45	39 (86%)	HFNT: 13 (33%) NIV: 6 (15%) NRS: 19 (49%)	NA	NIV/ HFNT
Vivarelli M. ²⁹ <i>Italian Journal of Medicine 2013</i>	Italy	Prospective MC	H1N1 19	19 (100%)	NIV: 14 (74%)	NIV: 2 (14%)	BIPAP/ PSV/ CPAP
Nicolini A. ²⁸ <i>Minerva Anestesiologia 2012</i>	Italy	Prospective MC	H1N1 98	98 (100%)	NIV: 60 (61%)	NIV: 13 (21%)	PSV/ CPAP
Rello J. ²⁶ <i>Critical Care 2009</i>	Spain	Retrospective MC	H1N1 32	24 (75%)	NIV: 8 (33%)	NIV: 6 (75%)	NIV/ CPAP
Rello J. ³⁰ <i>Journal of Critical Care 2012</i>	Spain	Post hoc	H1N1 35	30 (86%)	HFNT: 20 (67%)	HFNT: 11 (55%)	HFNT
Nin N. ³¹ <i>Journal of Critical Care 2011</i>	Spain	Prospective MC	H1N1 96	96 (100%)	NIV: 43 (45%)	NIV: 33 (77%)	NIV/ CPAP
Belenguer-Muncharaz A. ²⁷ <i>Medicina Intensiva 2011</i>	Spain	Retrospective SC	H1N1 10	5 (50%)	NIV: 5 (50%)	NIV: 0%	BIPAP/ CPAP
Masclans J. R. ²⁵ <i>Clin Microbiol Infect 2012</i>	Spain	Prospective MC	H1N1 685	489 (71%)	NIV: 177 (36%)	NIV: 105 (59%)	NIV/ CPAP
Marin-Corral J. ³² <i>Medicina Intensiva 2018</i>	Spain	Prospective MC	H1N1 2205	1380 (62,5%)	NIV: 775 (56%)	NIV: 454 (59%)	NIV/ CPAP
Hernández Garcés H. ³⁵ <i>Medicina Intensiva</i>	Spain	Retrospective SC	H1N1 54	49 (91%)	NIV: 43 (88%)	NIV: 18 (42%)	BIPAP/ CPAP ⁺

2020							
Brink M. ³⁶ <i>Acta Anaesthesiol Scand 2012</i>	Sweden	Retrospective MC	H1N1 126	93 (74%)	NIV: 67 (72%)	NIV: 45 (67%)	NIV/ CPAP
Linko R. ³⁷ <i>Acta Anaesthesiol Scand 2011</i>	Finland	Prospective MC	H1N1 132	103 (78%)	NIV: 36 (35%)	NIV: 46 (56%)	NIV/ CPAP
Bitar A. ⁴³ <i>Emerging Infectious Diseases 2016</i>	USA	Retrospective	H1N1 90	18 (20%)	NIV: 12 (13%)	NA	BIPAP/ CPAP
Kumar A. ³⁸ <i>JAMA-EXPRESS 2009</i>	Canada	Prospective MC	H1N1 168	136 (81%)	NIV: 55 (40%)	NIV:47 (85%)	NIV/ CPAP
Timenetsky K. T. ³⁹ <i>BMC Research Notes 2011</i>	Brazil	Retrospective SC	H1N1 20	14 (70%)	NIV: 12 (86%)	NIV: 7 (58%)	BIPAP/ CPAP
Estenssoro E. ²⁴ <i>AJRCCM 2010</i>	Argentina	Prospective MC	H1N1 337	337 (100%)	NIV: 64 (19%)	NIV: 21 (33%)	NIV/ CPAP
Rios F. G. ²³ <i>Critical Care 2011</i>	Argentina	Prospective MC	H1N1 178	178 (100%)	NIV: 49 (28%)	NIV: 46 (94%)	BIPAP/ CPAP
Chawla R. ⁴⁰ <i>Indian J Crit Care Med 2013</i>	India	Retrospective SC	H1N1 77	36 (47%)	NIV: 17 (47%)	NIV: 6 (31%)	BIPAP/ CPAP
Gogia A. ³³ <i>Curr Med Res Pract 2017</i>	India	Prospective SC	H1N1 151	32 (21%)	NIV: 10 (31%)	NA	BIPAP/ CPAP
Koegelenberg C. F. ⁴² <i>Oxford journals 2010</i>	South Africa	Prospective SC	H1N1 19	19 (100%)	NIV: 6 (31%)	NIV: 4 (67%)	PSV/ CPAP
Bai L. ⁴¹ <i>CHEST 2011</i>	China	Prospective SC	H1N1 65	25 (38.5%)	NIV: 16 (60%)	NIV: 10 (41%)	NIV/ CPAP
Zhang P. J. ³⁴ <i>BMC Infectious Diseases 2012</i>	China	Retrospective	H1N1 394	186 (4%)	NIV: 83 (45%)	NIV: 45 (54%)	NIV/ CPAP
Cheung T.M.T. ⁴⁵ <i>CHEST 2004</i>	Hong Kong	Retrospective SC	SARS 20	20 (100%)	NIV: 20 (100%)	NIV: 6 (30%)	BIPAP/ CPAP

Zhao Z. ⁴⁶ <i>Journal of Medical Microbiology</i> 2003	China	RCT	SARS 190	NA	NIV: 60 (31%)	NA	NIV/ CPAP
Ramos J. M. ⁵¹ <i>Rev Esp Quimioter</i> 2016	Spain	Retrospective SC	Influenza 219	NA	NIV: 31 (14%)	NA	NIV
Edilboglu O. ⁴⁸ <i>Tuberk Toraks</i> 2018	Turkey	Retrospective SC	Influenza 22	22 (100%)	NIV: 22 (100%)	NIV: 14 (63%)	NIV
Ding L. ⁵² <i>Critical Care</i> 2020	China	Prospective MC	Influenza 20	20 (100%)	NIV: 20 (100%)	NIV: 9 (45%)	CPAP/ BIPAP ⁺ HFNT
Topoulos S. ⁴⁹ <i>Infection</i> 2019	Germany	Retrospective	Influenza/RSV 214	20 (9%)	NIV: 14 (70%)	NA	NIV
Rodríguez A. ⁵⁰ <i>Respiratory care</i> 2017	Spain	Post hoc analysis	Influenza 2480	1898 (76%)	NIV: 806 (42%)	NIV: 458 (57%)	NIV
Ko F. W. ⁵³ <i>CHEST</i> 2007	China	Prospective SC	COPD + viral infections 196	NA	NIV: 23 (9%)*	NA	NIV
Cameron R. J. ⁵⁴ <i>Intensive Care Med</i> 2006	Australia	Prospective	COPD + viral infections 105	105 (100%)	NIV: 61 (58%)	NA	NIV
Alraddadi B. M. ⁵⁵ <i>Influenza Other Respi Viruses</i> 2019	Saudi Arabia	Retrospective MC	MERS 302	302 (100%)	NIV: 105 (35%)	NIV: 97 (92%)	NIV

§: Nasal Mask; +: Oro-nasal Mask; Λ: Full Face; °: Helmet.

*Data are calculated on the 1300 patients with available respiratory support data.

NRS: noninvasive respiratory support; HFNT: High flow nasal cannula; NIV: noninvasive ventilation; BIPAP: Bilevel Positive Airway Pressure;

PSV: Pressure Support Ventilation; CPAP: Continuous Positive airway Pressure; Retrospective SC: Retrospective Single-center; Retrospective MC:

Retrospective Multi-center; Prospective SC: Prospective Single-center; Prospective MC: Prospective Multi-center; ARDS: Acute Respiratory Distress Syndrome; SARS: Severe Acute Respiratory Syndrome; MERS: Middle East respiratory syndrome; RSV: respiratory syncytial virus.

TITLES OF FIGURES

Figure 1. Noninvasive respiratory supports utilization rate among COVID-19 studies.

Each bar indicates the total percentage of noninvasive supports usage, black and white bars indicate proportions between NIV and HFNT.

*Huang C: only total data available with no distinction between NIV and HFNT

NIV: noninvasive ventilation; HFNT: High flow nasal therapy.

Figure 2 . Noninvasive respiratory supports utilization rate among H1N1 influenza studies.

Each bar indicates the total percentage of noninvasive supports usage, black and white bar indicate proportions between NIV and HFNT.

NIV: noninvasive ventilation; HFNT: High flow nasal therapy.

Figure 3. Noninvasive respiratory supports utilization rate among SARS/MERS studies.

Each bar indicates the total percentage of noninvasive supports usage, black and white bar indicate proportions between NIV and HFNT.

NIV: noninvasive ventilation; HFNT: High flow nasal therapy; SARS: Severe Acute Respiratory Syndrome; MERS: Middle East respiratory syndrome.

Figure 4. Droplets aerosolization distance.

NIV: noninvasive ventilation; HFNT: High flow nasal therapy; CPAP: continuous positive airway pressure.

Maximum exhaled air dispersion (m)	
Oxygen non-rebreathing mask (12 l/m)	< 0.1
Oxygen oro-nasal mask (10 l/m, more during coughing)	0.40
Oxygen nasal cannula (5 l/m)	1
Oxygen Venturi mask (FiO_2 40%)	0.33
HFNT (60 l/m)	0.17
CPAP nasal pillows (20 cmH ₂ O)	0.33
Jet nebulizer (severe lung injury)	0.80
NIV oro-nasal vented mask (IPAP/EPAP: 18/4 cmH ₂ O)	0.85
NIV oro-nasal mask with whisper (IPAP/EPAP: 18/4 cmH ₂ O)	> 0.95
NIV full-facemask vented (IPAP/EPAP: 18/5 cmH ₂ O)	0.92
NIV helmet with neck seal (IPAP/EPAP: 20/10 cmH ₂ O)	~ 0
NIV helmet without neck seal (IPAP/EPAP: 20/10 cmH ₂ O)	0.27